Warning: The NCBI web site requires JavaScript to function. more...
Estimating the cost of cervical cancer screening in five developing countries.
Goldhaber-Fiebert JD, Goldie SJ.
Cost Eff Resour Alloc. 2006 Aug 3;4:13.
Related citations
Final Report on Carcinogens Background Document for Styrene.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Final Report on Carcinogens Background Document for Formaldehyde.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, King J, Yi B, Ringers P, Blumenthal PD.
J Natl Cancer Inst. 2002 Oct 2;94(19):1469-83.
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP.
Pharmacoeconomics. 2004;22(6):389-411. Review.
Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC.
JAMA. 2001 Jun 27;285(24):3107-15. Erratum in: JAMA 2001 Sep 5;286(9):1026.
Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, Wright TC; Alliance for Cervical Cancer Prevention Cost Working Group.
N Engl J Med. 2005 Nov 17;353(20):2158-68.
Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
Goldie SJ, Kim JJ, Wright TC.
Obstet Gynecol. 2004 Apr;103(4):619-31.
Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
Kim JJ, Wright TC, Goldie SJ.
J Natl Cancer Inst. 2005 Jun 15;97(12):888-95.
Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
JAMA. 2002 May 8;287(18):2382-90.
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP, Dasbach EJ, Elbasha EH.
Pharmacoeconomics. 2005;23(11):1107-22. Review.
ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, Roberts C, Desai M, Peto J; ARTISTIC Trial Study Group.
Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv.
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ.
Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. Review.
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP.
J Manag Care Pharm. 2010 Apr;16(3):217-30. Review.
Cost-effectiveness of primary cytology and HPV DNA cervical screening.
Bistoletti P, Sennfält K, Dillner J.
Int J Cancer. 2008 Jan 15;122(2):372-6.
Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.
Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, Duffy S, Ritchie G, Kleijnen J, Westwood M.
Health Technol Assess. 2006 Jun;10(18):iii-iv, xi-259. Review.
Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C.
Gynecol Oncol. 2009 Feb;112(2):377-83. Epub 2008 Dec 11.
Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.
Arch Med Res. 2009 Aug;40(6):503-13.
Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Chernofsky M, Myers ER.
Obstet Gynecol. 2006 May;107(5):997-1005.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on